Unknown

Dataset Information

0

Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.


ABSTRACT:

Purpose

Efavirenz-based combination antiretroviral therapy (cART) is associated with neuropsychiatric adverse events. We investigated the time to onset, duration, clinical implications, impact of pharmacogenetic variations, and anti-tuberculosis co-treatment on efavirenz-associated neuropsychiatric manifestations.

Methods

Prospective cohort study of cART naïve HIV patients with or without tuberculosis (HIV-TB) co-infection treated with efavirenz-based cART. Rifampicin-based anti-tuberculosis therapy was initiated 4 weeks prior to efavirenz-based cART in HIV-TB patients. Data on demographic, clinical, laboratory, and a 29-item questionnaire on neuropsychiatric manifestations were collected for 16 weeks after cART initiation. Genotyping for CYP2B6, CYP3A5, SLCO1B1, and ABCB1 and quantification of efavirenz plasma concentration were done on the 4th and 16th week.

Results

Data from 458 patients (243 HIV-only and 215 HIV-TB) were analyzed. Overall incidence of neuropsychiatric manifestations was 57.6% being higher in HIV-only (66.7%) compared to HIV-TB patients (47.4%) (p?ConclusionsIncidence of neuropsychiatric manifestations during early initiation of efavirenz-based cART is high in Tanzanian HIV patients. Risk of neuropsychiatric manifestations is lower in HIV patients co-treated with rifampicin containing anti-TB compared to those treated with efavirenz-based cART only.

SUBMITTER: Mugusi S 

PROVIDER: S-EPMC6182598 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.

Mugusi Sabina S   Ngaimisi Eliford E   Janabi Mohammed M   Mugusi Ferdinand F   Minzi Omary O   Aris Eric E   Bakari Muhammad M   Bertilsson Leif L   Burhenne Juergen J   Sandstrom Eric E   Aklillu Eleni E  

European journal of clinical pharmacology 20180712 11


<h4>Purpose</h4>Efavirenz-based combination antiretroviral therapy (cART) is associated with neuropsychiatric adverse events. We investigated the time to onset, duration, clinical implications, impact of pharmacogenetic variations, and anti-tuberculosis co-treatment on efavirenz-associated neuropsychiatric manifestations.<h4>Methods</h4>Prospective cohort study of cART naïve HIV patients with or without tuberculosis (HIV-TB) co-infection treated with efavirenz-based cART. Rifampicin-based anti-t  ...[more]

Similar Datasets

| S-EPMC6721293 | biostudies-literature
| S-EPMC3145153 | biostudies-literature
| S-EPMC2933581 | biostudies-literature
| S-EPMC7306071 | biostudies-literature
| S-EPMC5488565 | biostudies-other
| S-EPMC6292957 | biostudies-literature
| S-EPMC7268026 | biostudies-literature
| S-EPMC5056298 | biostudies-literature
2022-09-13 | GSE199662 | GEO